Sun et al. (2016) reported that genetic or pharmacologic inhibition of Nrf2 expression/activity in HCC cells increased the anticancer activity of erastin and sorafenib in vitro, and in tumor xenograft models, Nrf2 is a key factor that determines the therapeutic response to ferroptosis-targeted therapies in HCC cells. Here, NFE2L2 is linked to neoplasm.